The DOI matches its Crossref record.
Reboxetine: tolerability and safety profile in patients with major depression
Abstract
Since reboxetine acts selectively on the reuptake of noradrenaline, it has a different side‐effects profile than drugs acting predominantly on the serotonin reuptake mechanism. Data from patients treated with reboxetine (n=1503) or placebo/comparator drugs (n=1027) show that reboxetine has no significant cardiovascular effects, a low potential for drug interactions, causes no significant impairment of cognitive or motor function and no increase in suicidal ideation. In contrast to certain serotonergic drugs, there is no evidence of any withdrawal syndrome upon abrupt discontinuation or tapering of reboxetine treatment. Sexual dysfunction appears in only a small fraction of the patients and mainly with doses higher than 8 mg daily. The rate of discontinuation due to adverse effects with reboxetine was not significantly different from that observed with placebo in short‐term studies. The level of efficacy and apparently favourable tolerability profile makes reboxetine an important alternative in the medical treatment of depressive illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
A review of the adverse effects and safety of noradrenergic antidepressants
Whiskey, E., & Taylor, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113492027 · Cited by 64
“About 18% of reboxetine-treated patients complain of constipation and 14-27% of patients have dry mouth during reboxetine treatment (Ban et al., 1998; Schatzberg, 2000; Tanum, 2000).”
BackgroundCardiovascular adverse effects of newer antidepressants
Mago, R., Tripathi, N., & Andrade, C. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.908709 · Cited by 54
Metadata
- Authors
- Tanum, L.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2000-06
- Volume
- 101
- Issue
- s402
- Pages
- 37-40
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2167880945
- Cited by
- 198
- References
- 0
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reboxetine: tolerability and safety profile in patients with major depression. https://app.cochat.ai/papers/10.1034/j.1600-0447.2000.02606.x
- The paper
- Tanum, L. (2000). Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatrica Scandinavica. https://doi.org/10.1034/j.1600-0447.2000.02606.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.